3rd Annual Guggenheim Healthcare Innovation Conference
Logotype for Beam Therapeutics Inc

Beam Therapeutics (BEAM) 3rd Annual Guggenheim Healthcare Innovation Conference summary

Event summary combining transcript, slides, and related documents.

Logotype for Beam Therapeutics Inc

3rd Annual Guggenheim Healthcare Innovation Conference summary

10 Nov, 2026

Editing platform

  • Base editing uses RNA-guided Cas9 targeting without double-stranded DNA breaks; attached deaminase enzymes enable A-to-G or C-to-T changes.

  • Four programs are in clinical development, spanning ex vivo sickle cell treatment and in vivo LNP-based editing for liver diseases.

Risto-cel for sickle cell disease

  • BEACON met all primary and secondary efficacy and safety endpoints; a BLA filing is targeted as early as year-end 2026.

  • Risto-cel showed the highest reported hemoglobin F, reduced hemoglobin S below 40%, normalized hemoglobin, and reduced blood viscosity.

  • Automated manufacturing supports reliable dosing; median mobilization was one, with the vast majority of trial participants requiring two or fewer mobilizations.

  • Dose is 3.5 million cells/kg; base editing requires fewer starting cells, while faster neutrophil engraftment may reduce infection risk and hospital stays.

In vivo programs

  • BEAM-302 for alpha-1 antitrypsin deficiency is in pivotal phase; FDA agreement supports accelerated approval, with pivotal completion expected in H1 2027.

  • At 60 mg, all patients reached the 11-micromolar total AAT threshold or higher; the FDA viewed the biomarker dataset as approvable for accelerated approval.

  • BEAM-301 for G6PC R83C showed two patients at 40 mg fasting for 15 hours versus a prior maximum of two hours; dose escalation is proceeding to 60 mg.

  • One BEAM-301 participant responded less, with compound heterozygosity and BMI 53 cited as possible factors; lower-dose participants are expected eventually to receive the optimal biological dose, without a timeline.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Beam Therapeutics